http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2277594-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4ff548dae58eeb810250f8b205c20e20 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-6615 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12M47-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M1-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-6615 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-50 |
| filingDate | 2005-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fbdb29b2f057d280d52155ba06d3c04 |
| publicationDate | 2011-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2277594-A2 |
| titleOfInvention | Lysis / resealing process and device for incorporating an active ingredient in erythrocytes |
| abstract | Lysis/resealing process for preparing erythrocytes which contain an active ingredient, the process comprising the following steps: n(1) - placing a globular concentrate in suspension in an isotonic solution having a haematocrit level which is equal to or greater than 65 %, with refrigeration at from + 1 to + 8 °C, n(2) - measuring the osmotic fragility based on a sample of erythrocytes from that same globular concentrate, preferably on a sample of the suspension obtained in step (1), n(3) - lysis and internalisation procedure of the active ingredient, inside the same chamber, at a temperature which is constantly maintained at from + 1 to + 8 °C, comprising allowing the erythrocyte suspension having a haematocrit level which is equal to or greater than 65 % and a hypotonic lysis solution which is refrigerated at from + 1 to + 8 °C, to circulate in a dialysis cart ridge; the lysis parameters being adjusted in accordance with the osmotic fragility previously measured; and n(4) - resealing procedure carried out in a second chamber at a temperature of from + 30 to + 40 °C by means of a hypertonic solution. |
| priorityDate | 2004-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 93.